Abstract #0584

T1 mapping of neuroblastoma pathology: insight from a computational pathology study in the Th-MYCN transgenic mouse model

Konstantinos Zormpas-Petridis¹, Matthew D. Blackledge¹, Matthew Clarke², Louis Chesler³, Yinyin Yuan², Simon P. Robinson¹, and Yann Jamin¹

¹Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, Sutton, United Kingdom, ²Division of Molecular Pathology, The Institute of Cancer Research, London, Sutton, United Kingdom, ³Division of Clinical Studies, The Institute of Cancer Research, London, Sutton, United Kingdom

A reduction in T₁ has been reported as a generic biomarker of successful treatment in the Th-MYCN model of neuroblastoma, a childhood tumor of the developing nervous system. The aim of this study was to decipher the pathological determinant(s) contributing to global and regional variations in native T₁ by comparison with R₂* maps and registered computed density maps of both segmented cells and classified cells, extracted from whole-slide digital pathology images in tumors arising in the Th-MYCN transgenic model of neuroblastoma.

This abstract and the presentation materials are available to members only; a login is required.

Join Here